HispanicBusiness

In fact, if approved, AntriaBio believes AB101 will result in greater patient compliance (once weekly delivery versus once daily). Keep in mind, also, that the number of just over 300 million individuals with diabetes is expected to grow to be 550 million by 2030.

AntriaBio proposes that AB101 would be administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level that supplements the effects of bolus insulin and complements the effects of other diabetes medications.

The firm has a very smart and efficient clinical approval pathway that includes for the possibility that AB101 may be able to be marketed in Russia while US and EU studies move forward at a slower pace.

This is a fascinating and innovative technology led by a group with plenty of product experience and we will follow this story as it unfolds.

In the meantime, given the share-count actually in the float currently, it may be wise for both traders and long-term holders to consider establishing positions in front of upcoming catalysts and before this marked biotech's popularity begins to spread.

Disclosure: Author M.E. Garza is Long ANTB

The full version of this report complete with presentation slide deck images chart can be found here:

http://www.biomedreports.com/20130222124061/once-a-week-insulin-shot-could-help-growing-diabetes-patient-base-and-spell-big-profits-for-investors.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com



Add to Digg Bookmark with del.icio.us Add to Newsvine



Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact